# Neal Bhadkamkar

> Neal Bhadkamkar is a Series A investor at Bold Capital Partners backing Therapeutics. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital)
- Location: Palo Alto, United States
- Total investments: 17
- Last investment: Jan 2026
- Lead investor: 35%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/neal-bhadkamkar/1/105/b50

Neal Bhadkamkar is a Series A investor at Bold Capital Partners in Palo Alto focused on Therapeutics and Biotechnology. Neal Bhadkamkar is the General Partner of Bold Capital Partners and Co-Founder and Managing Partner of Monitor Ventures. He is a former Member of the Research staff at Interval Research.Before co-founding Monitor Ventures, Neal had a successful career in technology commercialization. As VP of Manufacturing and Engineering at Zowie Intertainment,Neal managed the design and development of analog and digital chips, PC software, as well as complex plastic components. At Interval Research, Paul Allen's research and commercialization company, Neal served as a member of the research staff as well as headed the commercialization process. In that capacity, he was responsible for transforming mature research projects into spin-off companies. Neal started his business career at the Boston Consulting Group where he worked closely with Teymour Boutros-Ghali (the two have had a long-standing professional and personal relationship since).As a partner of Monitor Ventures, Neal focuses on transforming technologies for industrial and enterprise applications. Neal is a graduate of the Indian Institute of Technology in Electrical Engineering and holds an MBA from Harvard Business School and a Ph.D. in Electrical Engineering from Stanford University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 12% |
| Biotechnology | 2 | 12% |
| Chemical | 1 | 6% |
| Payments | 1 | 6% |
| Wellness | 1 | 6% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Series B | 3 | 18% |
| Series C | 2 | 12% |
| Seed | 1 | 6% |
| Series E | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 35% |
| Israel | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MagicCube | MagicCube is the Software Defined Trust (SDT) category with its software TEE-based platform. The technology enables large-scale deployment and management of IoT and mobile- secure solutions to consumers. | $10M | Venture - Series Unknown | Jan 11, 2026 |  |
| Discure Technologies | Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat and reverse degenerative disc disease (DDD), healing the disc, reducing pain, and restoring function to patients. | $11M | Series A | Sep 10, 2024 |  |
| Holoclara | Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules. | $16M | Series A | Jun 27, 2024 |  |
| Solarea Bio | Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals toprovide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt. | $15M | Series B | May 08, 2023 |  |
| Earth Force Technologies | Earth Force is a Vegetation Management System platform. | $8.6M | Seed | Nov 29, 2022 |  |
| Earth Force Technologies | Earth Force is a Vegetation Management System platform. | $8.6M | Seed | Nov 29, 2022 |  |
| MagicCube | MagicCube is the Software Defined Trust (SDT) category with its software TEE-based platform. The technology enables large-scale deployment and management of IoT and mobile- secure solutions to consumers. | $15M | Series C | Oct 14, 2021 |  |
| Solarea Bio | Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals toprovide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt. | $11.2M | Series A | Oct 19, 2020 |  |
| MagicCube | MagicCube is the Software Defined Trust (SDT) category with its software TEE-based platform. The technology enables large-scale deployment and management of IoT and mobile- secure solutions to consumers. |  | Series B | May 28, 2020 |  |
| MagicCube | MagicCube is the Software Defined Trust (SDT) category with its software TEE-based platform. The technology enables large-scale deployment and management of IoT and mobile- secure solutions to consumers. | $10M | Series A | Aug 08, 2017 |  |

10 of 17 investments shown.

## Co-investors
- [OVP Venture Partners](https://shizune.co/investors/profile/ovp-venture-partners) — VC Fund, 5 deals together
- [EPIC Ventures](https://shizune.co/investors/profile/epic-ventures) — VC Fund, 3 deals together
- [Life Science Angels](https://shizune.co/investors/profile/life-science-angels) — VC Fund, 3 deals together
- [Alley Robotics Ventures](https://shizune.co/investors/profile/alley-robotics-ventures) — VC Fund, 2 deals together
- [BP p.l.c.](https://shizune.co/investors/profile/bp-3) — VC Fund, 2 deals together
- [DSM Venturing](https://shizune.co/investors/profile/dsm-venturing) — VC Fund, 2 deals together

## About Bold Capital Partners

VC Fund · Santa Monica, United States

Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.

5 contacts available at Bold Capital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Teymour Boutros-Ghali | Managing Partner | https://shizune.co/investors/profile/teymour-boutros-ghali |
| Will Borthwick | Principal | https://shizune.co/investors/profile/will-borthwick |
| Emilio Diez Barroso | Partner | https://shizune.co/investors/profile/emilio-diez-barroso |
| Felicia Hsu | Investor | https://shizune.co/investors/profile/felicia-hsu |
| Maxx Bricklin | Partner | https://shizune.co/investors/profile/maxx-bricklin |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Neal Bhadkamkar invest in?

Neal Bhadkamkar invests primarily in Therapeutics, Biotechnology and Chemical startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Neal Bhadkamkar last invest?

The most recent investment recorded for Neal Bhadkamkar closed in Jan 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co